The short version of NAD+ salvage fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-29. Anything still debated is marked as such rather than presented as settled.
Research on NMN has focused on aging, metabolic regulation, exercise capacity, and insulin sensitivity, but findings are preliminary. Many human trials are small, short in duration, and use different endpoints, which complicates comparison across studies. No national regulator has approved NMN as a therapeutic drug for any indication. In some countries it is sold as a supplement or research chemical, while other jurisdictions have questioned its status under food or supplement laws. Claims about extending human lifespan or reversing aging are not supported by established clinical evidence.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms, including bacteria, plants, and mammals. Its structure consists of a nicotinamide ring attached to a ribose-phosphate group. NMN functions as an intermediate in the NAD+ salvage pathway, a recycling route that regenerates nicotinamide adenine dinucleotide. The enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+.
Dietary sources of NMN include small amounts in certain vegetables, fruits, and other foods, although exact values vary by sample and method. Endogenous NMN concentrations are tightly regulated and often low, making measurement in blood or tissues technically demanding. After oral intake, NMN is thought to be rapidly metabolized in the intestine and liver, and intact NMN may not reach all tissues at high levels. Some rodent studies report increases in tissue NAD+ after oral NMN, while human data remain limited and sometimes rely on blood NAD+ metabolites rather than direct tissue measures.
Commercial NMN is produced through enzymatic or chemical routes, and the resulting material can vary in purity, counterion, and residual solvent content. Buyers typically rely on certificates of analysis, but independent verification through third-party laboratories provides stronger assurance. Regulatory treatment differs by country; in the United States, NMN has been subject to shifting guidance about its status as a dietary supplement, while other markets permit sales under local rules. No universal pharmacopeial monograph exists for NMN, so specifications often come from suppliers, research protocols, or regional requirements.
Solid NMN is generally handled as a moisture-sensitive compound. Dry material stored desiccated at low temperature, protected from light, tends to remain stable for extended periods. Aqueous solutions are less stable and can undergo hydrolysis, especially at elevated temperature or alkaline pH. The anomeric form also matters: beta-NMN is the naturally occurring form, while alpha-NMN can appear as a synthetic impurity. Purity and storage conditions therefore influence both analytical results and experimental reproducibility.
Identity and purity are usually assessed with complementary methods. Nuclear magnetic resonance spectroscopy can confirm the molecular structure and distinguish anomeric forms. High-performance liquid chromatography with ultraviolet detection or mass spectrometry is common for assay and related-substance testing. Mass spectrometry also supports trace quantification in biological samples, often with isotope-labeled internal standards. Because NMN lacks a strong chromophore, some ultraviolet methods require careful wavelength selection or derivatization, and laboratories may validate each approach for its intended matrix.
| Property | Value | Notes |
|---|---|---|
| Chemical name | Nicotinamide mononucleotide | Nucleotide intermediate in NAD+ salvage pathway |
| Common abbreviation | NMN | Also written as β-NMN |
| Molecular formula | C11H15N2O8P | Uncharged parent form |
| Molar mass | 334.22 g/mol | Calculated from formula |
| CAS Registry Number | 1094-61-7 | For β-nicotinamide mononucleotide |
The biologically relevant form of NMN is generally the beta anomer, which is recognized by NMN adenylyltransferases. NMN is polar and water soluble, and it does not readily diffuse across lipid membranes without assistance. Whether intact NMN enters cells through a specific transporter remains an open question; some studies propose solute carrier family members, while other work favors extracellular dephosphorylation to nicotinamide riboside followed by uptake. This transport and compartmentalization debate affects how researchers interpret oral administration studies. The distinction between intracellular synthesis and extracellular delivery is central to current discussion.
Terminology around NMN can be confusing because several related compounds share the vitamin B3 family. Nicotinamide riboside is a nucleoside, whereas NMN is a nucleotide with a phosphate group, and NAD+ is a dinucleotide coenzyme rather than a simple precursor. Niacin and nicotinamide are also NAD+ precursors but follow different metabolic entry points. In commercial and scientific writing, NMN usually refers to beta-nicotinamide mononucleotide unless another form is specified. Consistent nomenclature helps distinguish chemical identity from proposed biological effects.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a pyridine nucleotide that consists of a nicotinamide ring, a ribose sugar, and a phosphate group. It is an intermediate in the salvage pathway for nicotinamide adenine dinucleotide, or NAD+, synthesis. In mammalian cells, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. Nicotinamide mononucleotide adenylyltransferases then convert NMN into NAD+. The core structure and enzymatic route are well established in biochemical literature.
As a commercial ingredient, nicotinamide mononucleotide is commonly supplied as a powder or capsule. Its stability depends on temperature, moisture, pH, and light exposure. Hydrolytic and thermal degradation can increase over time, so manufacturers and laboratories often store material cold and dry. Purity is typically assessed with chromatographic methods, and identity can be confirmed by mass spectrometry. Published stability data for specific finished products remain limited. More data would help define shelf life under real-world conditions.
Regulatory treatment varies by country. In the United States, NMN has been marketed as a dietary supplement, but the Food and Drug Administration has stated that it is excluded from the dietary supplement definition because it was authorized for investigation as a new drug before being marketed as a supplement. Other jurisdictions may treat it as a novel food, a supplement, or an unapproved drug ingredient. Import and sale rules can therefore differ substantially.
In the salvage pathway, NMN is generated from nicotinamide and 5-phosphoribosyl-1-pyrophosphate by the enzyme nicotinamide phosphoribosyltransferase. A second route produces NMN from nicotinamide riboside through phosphorylation by nicotinamide riboside kinases. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferases, often called NMNAT enzymes. This stepwise route allows cells to recycle nicotinamide and maintain NAD+ levels under changing metabolic conditions. The relative contribution of each route varies by tissue, species, and physiological state, and it remains an active area of research.
Research on NMN has expanded because NAD+ concentrations decline with age in some tissues and because NAD+ participates in energy metabolism, DNA repair, and signaling. Animal studies have reported changes in NAD+ levels after NMN administration, but human data are more limited and often focus on safety, pharmacokinetics, and biomarker changes. Questions remain about oral absorption, tissue distribution, and whether changes in blood NAD+ reflect changes inside specific organs. NMN is not an approved drug, and claims about its clinical effects should be distinguished from established biochemical findings.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide ring, a ribose sugar, and a phosphate group. The compound exists in cells as an intermediate in the production of nicotinamide adenine dinucleotide, a central redox cofactor. NMN is distinct from nicotinamide riboside, another related pyridine nucleotide, although the two compounds can converge in metabolic pathways. Its chemical formula is C11H15N2O8P, and it carries a net negative charge at physiological pH.
Analytical identification of NMN usually combines chromatographic separation with mass spectrometric detection. High-performance liquid chromatography coupled to tandem mass spectrometry is common for quantifying NMN in biological matrices and finished materials. Because NMN and related nucleotides share similar masses and retention behavior, method development must resolve potential interferences such as nicotinamide riboside and NAD+. Ultraviolet detection at approximately 260 nm can be used for purity checks when concentrations are sufficient. Nuclear magnetic resonance spectroscopy provides structural confirmation and can distinguish anomeric forms.
Stability testing examines how temperature, humidity, light, and pH affect NMN over time. The compound is generally considered hygroscopic and may degrade faster in aqueous solution than in dry powder form. Phosphate esters can hydrolyze under strongly acidic or alkaline conditions, and elevated temperatures accelerate such reactions. For storage, sealed containers at low temperature with desiccant are typical laboratory practices. Stability-indicating methods should separate NMN from its degradation products, including nicotinamide and nicotinamide riboside, so that purity loss can be tracked accurately.
Quality control for NMN materials typically includes identity, assay, impurity, and residual solvent tests. Certificates of analysis may report HPLC purity, water content, heavy metals, and microbial limits depending on the intended use. Because commercial NMN is sold as a research chemical or ingredient rather than a standardized drug in many jurisdictions, specifications can vary between suppliers. Independent verification can involve comparing retention time, mass spectrum, and NMR data against a reference standard. Open questions remain about how best to standardize purity claims and biological potency across different production methods.
The longest-lived vertebrates have been variously described as: Large parrots (macaws and cockatoos can live up to 80–100 years in captivity) Koi (a Japanese species of fish, allegedly living up to 200 years, though generally not exceeding 50 – a specimen named Hanako was reportedly 226 years old upon her death) Tortoises (Seychelles tortoise) (193 years) Tuatara (a New Zealand reptile species, 100–200+ years) Eels, the so-called Brantevik Eel (Swedish: Branteviksålen) is thought to have lived in a water well in southern Sweden since 1859, which makes it over 150 years old. It was reported that it had died in August 2014 at an age of 155. Whales (bowhead whale) (Balaena mysticetus about 200 years)—Although this idea was unproven for a time, recent research has indicated that bowhead whales recently killed still had harpoons in their bodies from about 1890, which, along with analysis of amino acids, has indicated a maximum life span of "177 to 245 years old". Greenland sharks are currently the vertebrate species with the longest known lifespan. An examination of 28 specimens in one study published in 2016 determined by radiocarbon dating that the oldest of the animals that they sampled had lived for about 392 ± 120 years (a minimum of 272 years and a maximum of 512 years). The authors further concluded that the species reaches sexual maturity at about 150 years of age.
=== Peritoneal folds === Understanding the macroscopic structure of the mesenteric organ meant that associated structures—the peritoneal folds and congenital and omental adhesions—could be better appraised. The small intestinal mesenteric fold occurs where the small intestinal mesentery folds onto the posterior abdominal wall and continues laterally as the right mesocolon. During mobilization of the small intestinal mesentery from the posterior abdominal wall, this fold is incised, allowing access to the interface between the small intestinal mesentery and the retroperitoneum. The fold continues at the inferolateral boundary of the ileocaecal junction and turns cephalad as the right paracolic peritoneal fold. This fold is divided during lateral to medial mobilization, permitting the surgeon to serially lift the right colon and associated mesentery off the underlying fascia and retroperitoneum. At the hepatic flexure, the right lateral peritoneal fold turns and continues medially as the hepatocolic peritoneal fold. Division of the fold in this location permits separation of the colonic component of the hepatic flexure and mesocolon off the retroperitoneum. Interposed between the hepatic and splenic flexures, the greater omentum adheres to the transverse colon along a further band or fold of peritoneum. Dissection through this allows access to the cephalad (top) surface of the transverse mesocolon. Focal adhesions frequently tether the greater omentum to the cephalad aspect of the transverse mesocolon.
The blood of 77% of the patients was incoagulable and 35% bled spontaneously, usually from the gums. Microhematuria was observed in 51% of the patients. Neurotoxic symptoms (ptosis, ophthalmoplegia, bulbar paralysis, and peripheral muscular weakness) developed in 85%. Endotracheal intubation was required in 42% and mechanical ventilation by 37%. Electrocardiographic (ECG or EKG) abnormalities were found in 52% of a group of 69 unselected patients. Specific antivenom raised against Australian taipan venom was effective in stopping spontaneous systemic bleeding and restoring blood coagulability but, in most cases, it neither reversed nor prevented the evolution of paralysis even when given within a few hours of the bite. However, early antivenom treatment was associated statistically with decreased incidence and severity of neurotoxic signs. The low case fatality rate of 4.3% is attributable mainly to the use of mechanical ventilation, a technique rarely available in Papua New Guinea. Earlier use of increased doses of antivenoms of improved specificity might prove more effective. The onset of symptoms is often rapid, and a bite from this species is a life-threatening medical emergency. Prior to the introduction of specific antivenom by the Commonwealth Serum Laboratories in 1956, a coastal taipan bite was nearly always fatal.
== Career == In the early 1920s, Harald Pedersen worked with Nobel laureate August Krogh (and others) at the Laboratory of Zoophysiology; his mechanical workshop produced machines used in early insulin production. In autumn 1923, his brother Thorvald was hired by Nordisk Insulinlaboratorium to analyse chemical processes in insulin production; Harald also worked at Nordisk.
== Cell types and locations == The spleen is the second largest unit of the mononuclear phagocyte system. The monocyte is formed in the bone marrow and transported by the blood; it migrates into the tissues, where it transforms into a histiocyte or a macrophage. Macrophages are diffusely scattered in the connective tissue and in liver (Kupffer cells), spleen and lymph nodes (sinus histiocytes), lungs (alveolar macrophages), and central nervous system (microglia). The half-life of blood monocytes is about 1 day, whereas the life span of tissue macrophages is several months or years. The mononuclear phagocyte system is part of both humoral and cell-mediated immunity. The mononuclear phagocyte system has an important role in defense against microorganisms, including mycobacteria, fungi, bacteria, protozoa, and viruses. Macrophages remove senescent erythrocytes, leukocytes, and megakaryocytes by phagocytosis and digestion.
Sources: en.wikipedia.org
== Further reading == Oliver, Brian; Devitt, Catherine; Park, Grace; Razak, Alina; Liu, Sun Mei; Bergese, Sergio D. (2025). "Drugs in Development to Manage Acute Pain". Drugs. 85 (1): 11–19. doi:10.1007/s40265-024-02118-0. PMID 39560856. Broadfoot, Marla (20 August 2024). "New Painkiller Could Bring Relief to Millions—Without Addiction Risk". Scientific American. Archived from the original on 30 December 2024. Retrieved 20 July 2026.
== Education == He studied chemistry at the Eötvös Loránd University (Budapest), where he graduated in 1973 and received a PhD in biochemistry in 1976. He worked as a postdoctoral research fellow at the University of California, San Francisco in 1978-1979.
These values are much greater than the oxide's, but still a few orders of magnitude lower than those of pristine graphene. Recently, the synthetic protocol for graphite oxide was optimized and almost intact graphene oxide with a preserved carbon framework was obtained. Reduction of this almost intact graphene oxide performs much better and the mobility values of charge carriers exceeds 1000 cm2/Vs for the best quality of flakes. Inspection with the atomic force microscope shows that the oxygen bonds distort the carbon layer, creating a pronounced intrinsic roughness in the oxide layers which persists after reduction. These defects also show up in Raman spectra of graphene oxide. Large amounts of graphene sheets may also be produced through thermal methods. For example, in 2006 a method was discovered that simultaneously exfoliates and reduces graphite oxide by rapid heating (>2000 °C/min) to 1050 °C. At this temperature, carbon dioxide is released as the oxygen functionalities are removed and it explosively separates the sheets as it comes out. The temperature of reduction is important for the oxygen content of the final product, with higher degree of reduction for higher reduction temperatures. Exposing a film of graphite oxide to the laser of a LightScribe DVD has also revealed to produce quality graphene at a low cost. Graphene oxide has also been reduced to graphene in situ, using a 3D printed pattern of engineered E. coli bacteria. Coupling of graphene oxide with biomolecules such as peptide, proteins and enzymes enhances its biomedical applications.
== Antigenic immunogenic potency == Many lipids and nucleic acids are relatively small molecules and/or have non-immunogenic properties. Consequently, they may require conjugation with an epitope such as a protein or polysaccharide to increase immunogenic potency so that they can evoke an immune response.
Sources: en.wikipedia.org
=== 2 December === Ukrainian Presidential Advisor Mykhailo Podolyak claimed that 10–13,000 Ukrainian soldiers have been killed since 24 February, the figure last given in August was 9,000. The Ukrainians struck a Russian concentration near Starobilsk, in the rear area of Luhansk Oblast, reportedly killing 14 Russian personnel and wounding 30.
== Relationship with humans == While not under human threat, the Atlantic blue tang is caught for commercial fishing, but maintains little importance to Caribbean industry. It is also used, though rarely, as bait. It is also common in the aquarium trade.
In the case of chain-end scission, monomers are released and this process is referred to as unzipping or depolymerization. Which mechanism dominates will depend on the type of polymer and temperature; in general, polymers with no or a single small substituent in the repeat unit will decompose via random-chain scission. The sorting of polymer waste for recycling purposes may be facilitated by the use of the resin identification codes developed by the Society of the Plastics Industry to identify the type of plastic.
Sources: en.wikipedia.org
NMN is nicotinamide mononucleotide, a nucleotide intermediate in the NAD+ salvage pathway. Cells use it to help regenerate NAD+, a coenzyme involved in energy metabolism and cellular signaling. It is present naturally in many organisms and is also produced synthetically for research and consumer products.
NMN is the immediate precursor to NAD+ in the salvage pathway. The enzyme NMN adenylyltransferase adds an adenylate group to NMN to form NAD+. Because NAD+ levels decline with age in some tissues, researchers study whether raising NMN availability can influence NAD+ metabolism.
No. Human evidence is limited, and no regulatory agency has approved NMN for treating or preventing aging. Some trials measure NAD+ metabolites or metabolic markers, but their results do not establish a clinical benefit. Larger, longer studies with standardized endpoints are needed.
Purity is commonly measured by high-performance liquid chromatography with ultraviolet or mass spectrometric detection. Nuclear magnetic resonance can confirm identity and anomeric composition. Water content and residual solvents may be tested separately.